ACS Chem Biol by Zabala, Angelica O. et al.
Fungal Polyketide Synthase Product Chain-Length Control by
Partnering Thiohydrolase
Angelica O. Zabala,† Yit-Heng Chooi,§ Moon Seok Choi,† Hsiao-Ching Lin,† and Yi Tang*,†,‡
†Department of Chemical and Biomolecular Engineering and ‡Department of Chemistry and Biochemistry, University of California,
Los Angeles, California 90095, United States
§Research School of Biology, Australian National University, Canberra, ACT 0200, Australia
*S Supporting Information
ABSTRACT: Fungal highly reducing polyketide synthases
(HRPKSs) are an enigmatic group of multidomain enzymes
that catalyze the biosynthesis of structurally diverse com-
pounds. This variety stems from their intrinsic programming
rules, which permutate the use of tailoring domains and
determine the overall number of iterative cycles. From genome
sequencing and mining of the producing strain Eupenicillium
brefeldianum ATCC 58665, we identified an HRPKS involved
in the biosynthesis of an important protein transport-inhibitor
Brefeldin A (BFA), followed by reconstitution of its activity in
Saccharomyces cerevisiae and in vitro. Bref-PKS demonstrated
an NADPH-dependent reductive tailoring specificity that led
to the synthesis of four different octaketide products with
varying degrees of reduction. Furthermore, contrary to what is expected from the structure of BFA, Bref-PKS is found to be a
nonaketide synthase in the absence of an associated thiohydrolase Bref-TH. Such chain-length control by the partner
thiohydrolase was found to be present in other HRPKS systems and highlights the importance of including tailoring enzyme
activities in predicting fungal HRPKS functions and their products.
Fungal polyketides constitute an important group of naturalproducts that includes statins, antibiotics, and anticancer
agents.1,2 The biosynthesis of polyketide in fungi is performed
by Type I iterative polyketide synthases (IPKSs), which are
multidomain megasynthases.3 The highly reducing IPKSs
(HRPKSs) are a large subgroup of the IPKSs that are
associated with the biosynthesis of highly reduced compounds,
such as lovastatin and fumonisin. The minimal PKS domains of
HRPKSs, which consist of ketosynthase (KS), malonyl-
CoA:acyl carrier protein transacylase (MAT), and acyl carrier
protein (ACP), catalyze the selection of malonyl building
blocks and the repeated Claisen-like chain extension steps.
HRPKSs also consist of a set of tailoring domains, including
ketoreductase (KR), dehydratase (DH), enoylreductase (ER),
and the Cα-methyltransferase (MT). Although the domain
organization of HRPKSs bears strong resemblance to that of
mammalian fatty acid synthases (FASs), the HRPKSs operate
in a much more sophisticated fashion.4 Most notably, the
HRPKSs use the single set of tailoring domains in different
permutations during every extension cycle, which results in the
high degree of variability at individual α- and β-positions in the
products. Product chain-length control also varies between
different HRPKSs, which results in polyketides that have a wide
range of sizes. Additionally, HRPKSs differ from FASs in that
there is no dedicated and fused thioesterase (TE) domain at the
C-terminus of the megasynthase and instead rely on the in trans
interaction with discrete TE or acyltransferase-like enzymes for
product release.2 Our current understanding of these unique
features of HRPKSs has remained at an early stage, thereby
limiting our ability to link reduced polyketides to correspond-
ing HRPKSs and to predict product structures from the vast
number of HRPKSs identified from fungal genome sequencing
efforts.
In order to better understand these enigmatic features of
HRPKSs, it is important to work with a suitable model system
for biochemical analysis. First, the model HRPKS should be a
standalone enzyme that generates a product of substantial chain
length that could be detected and analyzed (i.e., UV-active).
This circumvents the dependence on downstream enzymes
(e.g., other PKSs) for further modifications that convolutes
product analysis. Second, the HRPKS should be programmed
to synthesize a product with variable degrees of β-reduction
within each extension cycle to allow investigation of the
permutative tailoring rules. Lastly, it is ideal to work with an
HRPKS that is involved in the biosynthesis of a bioactive
polyketide product to aid the re-engineering of the HRPKS for
analogue generation.
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Several HRPKSs involved in the biosynthesis of pharmaceuti-
cally important polyketides have been investigated, such as
LovB and Hpm8 that are responsible for the biosynthesis of
lovastatin and hypothemycin, respectively. In the LovB system,
however, a yet unresolved Diels−Alder cyclization step
embedded among the chain extension steps has complicated
analysis of the HR-PKS alone.5,6 On the other hand, HRPKSs
from resorcylic acid lactone (RAL) pathways (such as Hpm8)
and from HRPKS-nonribosomal peptide synthetase (NRPS)
hybrids require downstream enzymes/domains for product
transfer and further modification, which represents an added
level of complexity in deconvoluting HRPKS functions and
products.7−9
In this study, we chose the HRPKS responsible for brefeldin
A (BFA) as a model system (Figure 1). BFA (1) is a protein-
transport inhibitor isolated from several species of filamentous
fungi.10−14 It is used to study protein transport among
eukaryotes but has also been found to have antiviral, antifungal,
and antitumor properties.15 The polyketide origin of this 16-
membered macrolactone was previously established through
feeding studies with labeled acetate.16−18 The proposed
biosynthesis of BFA involves formation of an acyclic polyketide
chain that is differentially tailored throughout the backbone
(Figure 1). The presence of the terminal hydroxyl group, along
with the strategically positioned double bonds, is proposed to
enable cyclization of the acyclic precursor into the fused,
bicyclic structure seen in BFA. We hypothesized that a single
HRPKS should be sufficient to generate the entire carbon
backbone without the need for an additional PKS. If the acyclic
product indeed contains conjugated double bonds as proposed,
the biosynthetic product should be readily identifiable and
isolated. Collectively, the BFA HRPKS appears to fit the mold
as a good model HR-PKS for biochemical analysis. Here, we
first identified the HRPKS most likely responsible for BFA
biosynthesis from Eupenicillium brefeldianum ATCC 58665. We
further demonstrate that using a product-based assay,
important programming rules of HRPKSs were elucidated,
including NADPH concentration-dependent extent of reduc-
tion and the control of HRPKS product chain length by an
associated discrete thiohydrolase (TH). These insights further
improve our understanding of how HRPKSs function.
Figure 1. Putative biosynthethic pathway for 1. The HRPKS is proposed to synthesize the precisely reduced octaketide precursor, which could then
be directly offloaded by the thiohydrolase enzyme followed by a P450-mediated formation of the cyclopentane ring and macrocyclization to afford
the 7-deoxy BFA 2 (top scheme). Alternatively, the first ring annulation can also occur on the ACP-tethered intermediate before the thiohydrolase
release and lactonization (bottom scheme). The C7-hydroxylation is believed to be the final step in the process to obtain the final structure of 1.
Figure 2. Transcriptional analysis of genes in Contig_286 determines the putative boundary of the bref cluster. (A) Arrangement of genes in
Contig_286. (B) RT-PCR analysis on the annotated genes within the contig. The template mRNA was extracted from a Day2 BFA-producing
culture of E. brefeldianum in the optimized production media, MEM.
ACS Chemical Biology Articles
dx.doi.org/10.1021/cb500284t | ACS Chem. Biol. 2014, 9, 1576−15861577
■ RESULTS AND DISCUSSION
Identification of the Brefeldin A PKS by Bioinformatic
and Transcription Analysis. The genomic DNA of the BFA-
producing strain E. brefeldianum ATCC 58665 was sequenced
using Roche (454) GS FLX Titanium series and Illumina HiSeq
2000. The resulting GS FLX Titanium reads were first
assembled using GS de novo assembler; the output contigs in
FASTA format were then combined with the supplementary
HiSeq 2000 reads in a hybrid assembly using the Geneious
Assembler embedded in the Geneious software suite.19 The
hybrid assembly generated 708 scaffolds consisting of nearly 36
Mbases of nonredundant reads that roughly reflect the E.
brefeldianum genome size. A local BLAST database was created
using the scaffolds. Using the KS domain of the nonaketide
synthase LovB as a query sequence, 24 putative PKSs were
identified: 11 HRPKSs; eight nonreducing PKSs (NRPKSs);
two partially reducing PKSs (PRPKS); and two HRPKS-NRPS
hybrids (Supplementary Figure S1). The lack of Cα-
methylation in BFA excluded the MT-containing HRPKSs,
narrowing down the search to five HRPKS-containing gene
clusters. Subsequently, RT-PCR was performed on the mRNA
of the BFA-producing culture to determine the transcription of
the HRPKS genes, of which only Contig_286 PKS was highly
transcribed at the time point that coincided with BFA
production (Figure 2 and Supplementary Figure S2), indicating
the high likelihood of this HRPKS being involved in BFA
biosynthesis.
The HRPKS of Contig_286 (orf 7) contains the following
domains linearly juxtaposed from N- to C-terminus: KS, MAT,
DH, ER, KR, and ACP. Using the maximum likelihood
statistical method on MEGA Version 5, a phylogenetic tree
with HRPKSs of known natural products was constructed.20
Contig_286 HRPKS claded with those that biosynthesize
relatively longer (>C10) acyclic polyketides such as the polyene
portion of fumagillin and fumonisin (Supplementary Figure
S3). The closest homologue is an uncharacterized HRPKS from
Trichoderma virens Gv29-8, TRIVIDRAFT_151590 (59%
identity, 73% similarity). Within the 37,663 bp of Contig_286,
nine other open-reading frames (ORFs) were identified using
Softberry prediction (Table 1). These include an α−β
hydrolase (orf 2), which interestingly has the closest homo-
logue, TRIVIDRAFT_53350 (60%, 77%), encoded immedi-
ately upstream of the TRIVIDRAFT_151590 PKS gene in T.
virens Gv29-8. Hence, this may be the partnering enzyme
involved in the release of the ACP-tethered polyketide thioester
product via either hydrolysis to yield an acyclic product (as a
thiohydrolase) or macrocyclization to yield a cyclized product
(Figure 1). The neighboring genes are consistent with that of a
possible BFA biosynthetic gene cluster, including four genes
encoding P450 monooxygenases (orfs 3−6). Previous feeding
studies have shown that the C4 and C7 hydroxylation in BFA
resulted from oxidative tailoring, while the cyclopentane ring
formation was similarly proposed to be P450-mediated.17,21
Hence the collection of P450s here may be responsible for
these transformations on the polyketide product. To analyze if
these genes are co-transcribed with the HRPKS gene in this
cluster, a transcriptional analysis was performed using gene-
specific primers (Figure 2B). All P450s and TH encoding genes
were highly transcribed in the producing culture, along with
orf 8 of unknown function. These genes were putatively
assigned to comprise the bref cluster, with the HRPKS and
TH renamed to Bref-PKS and Bref-TH, respectively.
Cloning and Expression of Bref-PKS and Bref-TH. The
producing strain E. brefeldianum ATCC 58665 is a non-
sporulating filamentous fungi, and attempts at genetic
manipulation were futile due to the multinucleated protoplasts.
To examine the activity and product of the Bref-PKS, the 7.1-kb
intron-less gene was assembled from five cDNA fragments and
placed under control of the ADH2 promoter by yeast
recombination in S. cerevisiae BJ5464-NpgA (Supplementary
Figure S4A).5 Subsequently, BJ5464-NpgA harboring the Bref-
PKS expression plasmid was cultured and grown to stationary
phase for protein expression. The hexahistidine-tagged Bref-
PKS was solubly expressed and was purified via nickel affinity
chromatography at a yield of 2 mg/L (Supplementary Figure
S4C). The intron-less gene encoding Bref-TH was similarly
constructed from cDNA and was subsequently expressed in E.
coli BL21(DE3) via an IPTG-inducible T7 promoter and
purified using nickel affinity chromatography (Supplementary
Figure S4B and C).
We first assayed the activities of the minimal PKS domains
(KS, MAT, and ACP) by incubating Bref-PKS with 2 mM
malonyl-CoA in PBS buffer, pH 7.4. In the absence of the
reducing cofactor NADPH, the reductive domains are expected
to be inactive and should yield an unreduced polyketide
product. After 16 h, the reaction was either extracted directly or
first treated with 1 M NaOH followed by extraction for product
analysis. In the absence of base hydrolysis, no product was
recovered. With NaOH treatment, we observed the production
of 4-hydroxy-6-methyl-2H-pyran-2-one (TKL) (Supplementary
Figure S5), which forms through the spontaneous cyclization
and release of the unreduced triketide.22 This result indicates
that the minimal PKS components were active and product
release from the PKSs requires additional factors.
Reconstitution of Bref-PKS Activities. Most HRPKSs do
not have a dedicated domain for product offloading, relying
instead on an in trans acyltransferase or TH to release the
polyketide from the ACP tether.2 Such partnering enzyme plays
an important role in terminating the chain elongation and
consequently in determining the length of the final product. To
investigate the influence of the in trans Bref-TH on HRPKS







orf1 F-box domain protein Aspergillus oryzae RIB40 BAE55018
(26/42)
orf 2/bref-TH α−β hydrolase Trichoderma virens Gv29-8
TRIVIDRAFT_53350 (60/77)
orf 3 cytochrome p450 Bipolaris maydis C5
COCHEDRAFT_1151230
(42/60)
orf4 cytochrome p450 Macrophomina phaseolina
MS6MPH_06433 (46/61)
orf5 cytochrome p450 Aspergillus oryzae CYP628C1
(52/70)
orf6 cytochrome p450 Macrophomina phaseolina
MPH_06428 (46/64)








orf 9 WD-40 Aspergillus terreus
NIH2624 ATEG_09923 (52/67)
orf10 kinesin Bipolaris victoriae
FI3 COCVIDRAFT_89854
(71/80)
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function, the purified enzyme was added to the Bref-PKS in
vitro reaction at an equimolar ratio (20 μM) with 2 mM
malonyl-CoA and 10 mM NADPH. The reaction was left at RT
for 16 h and was extracted with ethyl acetate and analyzed by
LC−MS. Four relatively hydrophobic compounds 3−6
emerged at the end of the gradient (5%−95% acetonitrile in
H2O, 30 min), with 3 being the dominant product (Figure 3A).
The corresponding masses for compounds 3, 4, 5, and 6 are
264, 268, 264 and 266, respectively (Supplementary Figure S6).
Compounds 3 and 5 displayed λmax of 260 nm, indicating the
presence of a slightly conjugated structure, while compounds 4
and 6 did not have significant absorption above 220 nm. The
masses of these compounds are consistent with that of an
octaketide that has undergone several reductive modifications
(for reference, the molecular weight of palmitic acid is 256).
In order to isolate sufficient amounts of 3−6 for structure
elucidation, Bref-PKS and Bref-TH were co-expressed under
the ADH2 promoter in the yeast host. Compounds 3 and 5
were harvested after 36 h of inoculation (1 and 0.5 mg/L final
yield, respectively), while 4 and 6 were extracted after 72 h (2
and 4 mg/L final yield, respectively), depending on their
highest production period (Figure 3B). Both 3 and 5
disappeared at the 72 h time point, suggesting the possible
conversion to 4 and 6, respectively. Each compound was
purified to homogeneity and subjected to full NMR spectros-
copy to elucidate their structures.
From the NMR spectra (Supplementary Table S1 and Figure
S15), 3 is determined to be a linear 16-carbon carboxylic acid
(δC1 171.30) (Figure 3C). The
1H NMR spectrum revealed
three olefinic groups, one oxygenated methine, seven
methylene groups and one methyl group. Based on COSY
correlations, two of the double bonds (C2−C3 and C4−C5)
form a diene that by HMBC correlations, was further
conjugated to carbonyl C1. This conjugated dienoic acid
accounts for the higher λmax 260 nm of 3 compared to BFA
(λmax= 220 nm). Additionally, the large coupling constants of
the connected protons (JHH 15.3) indicate trans configurations
of the double bonds. The remaining olefinic carbons are found
to be at the C10−C11 position from detailed analysis of the
COSY and HMBC correlations. The position of the C−OH
group at C15 was confirmed by the direct correlation of the
doublet C16 methyl protons to the oxygenated methine group.
To determine whether this compound is a macrolactone or an
acyclic molecule, we compared the carbon chemical shift of
C15 to the corresponding carbons in BFA and in an uncyclized
BFA analogue. The C15 chemical shift of 3 (δC15 68.5)
accorded with the uncyclized form (δC 69.3),
14 as opposed to
the slightly downfield shift in the lactone (δC 71.8).
23
The structure of 4 (m/z = 267 [M + H]+) was similarly
elucidated from the 1D- and 2D- NMR spectra and from
comparison to 3. Instead of the olefinic protons (δH 5.78, 7.22)
at the C2−C3 position, the C2−C3 carbons in 4 were found to
have methylene protons (δH 2.27, 2.31) that were connected to
the C4−C5 double bond in COSY (Supplementary Table S1
and Figure S16). This is in accordance with the loss of
conjugation in the molecule (λmax 220 nm) relative to 3. The
rest of the NMR signals of 4 are consistent with 3. Interestingly,
5 (m/z = 265 [M + H] +, λmax 260 nm) and 6 (m/z = 267 [M +
H] +, λmax 220 nm) were found to be structurally related to 3
and 4, respectively, differing by only the absence of the C15
hydroxyl group (δC15 68.5, δH15 3.71). Instead, an aliphatic
carbonyl signal (δC15 212) was observed in their respective
13C
NMR spectra, which was validated by HMBC correlations and
by the appearance of C16 methyl group as a singlet
(Supplementary Table S1 and Figures S14 and S15).
It is noteworthy that several important structural features of
3 are consistent with that of BFA including the C16 backbone.
Additionally, the C2−C3 and C10−C11 olefinic groups in 3 are
retained in BFA. The terminal hydroxyl group that is important
for macrocyclization to form BFA is also present. On the other
hand, while not observed in BFA, the C4−C5 double bond in 3
appears to be well-positioned for formation of the cyclopentane
Figure 3. In vitro products of Bref-PKS and Bref-TH are acyclic octaketides with variable degrees of β-reduction. (A) HPLC and EIC trace of the in
vitro reaction between Bref-PKS and Bref-TH. (B) Production of compounds 3−6 from the S. cerevisiae-NpgA strain co-expressing Bref-PKS and
Bref-TH. Notice the change in the production profile between days 1 and 3. The compounds were purified according to their peak production
period. (C) Elucidated structures of compounds 3−6 from the corresponding NMR spectra.
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ring in 1, presumably mediated by a P450 oxygenase encoded
in the bref cluster (Figure 1 and Supplementary Figure S14).
The structural parallels, both in size and sites of unsaturation/
hydroxylation, between 3 and BFA therefore strongly indicate
Bref-PKS is indeed the HRPKS involved in BFA biosynthesis.
The discovery of compounds 3−6 containing varying degrees
of β-reduction by Bref-PKS is unexpected. In generation of the
ketones 5 and 6, it appears the KR domain is prone to skipping
ketoreduction of the diketide intermediate, which results in the
C15 hydroxyl group. To further investigate the effect of
NADPH concentration on the reductive programming rules of
Bref-PKS, we performed in vitro assays by varying the NADPH
concentrations from 0.5 to 10 mM. While 3 remained as the
dominant product at NADPH concentrations higher than 2
mM, compound 5 was found to be the dominant product at
lower but still physiologically relevant concentration (<2 mM)
(Supplementary Figure S9). Hence, the KR domain is highly
sensitive to availability of reducing cofactors, albeit only at the
first ketoreduction step during Bref-PKS function. Interestingly,
the C15 ketone observed in 5 is also found in the 7-
dehydrobrefeldin A acid analogue that contains the cyclo-
pentane ring but is not macrocyclized.14 Therefore, the KR
domain may indeed be imprecisely programmed to act at the
C15 ketone in the native producer as well. Such NADPH-
dependent tailoring can add another degree of complexity to
HRPKSs in generating diversity among fungal polyketides.
The other octaketide products of Bref-PKS, 4 and 6, lack the
α−β double bond (C2−C3) observed in BFA and in 3 and 5.
Both were minimally produced in vitro but were the end
products in the yeast in vivo culture after more extended
fermentation (Figure 3B). The accumulation of 4 and 6 in yeast
coincided with the disappearance of 3 and 5, which strongly
suggests the enoylreduction of 3 and 5 by endogenous yeast
enzymes. This was further confirmed by the bioconversion
experiments with purified 3 and 5, in which both compounds
were fully converted into 4 and 6, respectively, by
untransformed S. cerevisiae BJ5464-NpgA within 24 h of
addition to the culture (Supplementary Figure S7). However,
the production of 4 and 6 in the in vitro assay also suggests that
the ER domains of Bref-PKS can partially reduce the enoyl
during the last iteration. No aberrant enoylreduction of the
C4−C5 and C10−C11 positions were observed among the
products, therefore pointing to a “specific overreduction” of the
ER domain at the last iteration.
Bref-TH Controls the Programmed Release of the
Octaketide Product from Bref-PKS. Having reconstituted
the activities of the Bref-PKS, we then investigated the role of
Bref-TH in chain termination and product release. The Bref-
PKS assay was repeated without Bref-TH for 16 h, followed by
Figure 4. In vitro reactions with Bref-PKS demonstrate the TH-controlled PKS chain length release. (A) EIC spectra of the in vitro reactions showed
the variation in the product profiles of Bref-PKS with Bref-TH; Bref-PKS with base hydrolysis; Bref-PKS with Bref-TH H276A; and Bref-PKS with
other in trans releasing enzymes CazE and Fma-AT. The reactions consist of 20 μM Bref-PKS, 2 mM mCoA, and 10 mM NADPH with either 20
μM concentration of the releasing enzyme or base hydrolysis (1 M NaOH at 65 °C for 10 min). (B) Proposed structures of 7 and 8.
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either direct extraction with ethyl acetate or pretreatment with
1 M NaOH at 65 °C (base hydrolysis) before extraction. The
amount of product turnover decreased significantly (10-fold) in
the absence of Bref-TH, consistent with the proposed role of
the hydrolase in facilitating chain release. When subjected to
base hydrolysis or upon subsequent addition of equimolar
amount of Bref-TH after 16 h, a higher level of product release
was observed (Supplementary Figure S10). The octaketides 3−
6 were recovered as previously, with the level of 4 now similar
to that of 3. The increased amount of ER over-reduction in the
absence of Bref-TH may be due to stalling of the polyketide
products on the Bref-PKS in the absence of TH-mediated
release.
More importantly, the two new products 7 (m/z 295 [M +
H]+) and 8 (m/z 297 [M + H]+) were isolated from the above
Bref-PKS assay, with 7 now being the dominant product of all
polyketide products (Figure 4A and Supplementary Figure
S10). Both compounds displayed λmax of 215 nm, which hints at
the absence of conjugated dienoic acid moiety. The +28 mu
increase in masses of 7 and 8 compared to that of 3 and 5
suggests the incorporation of a completely reduced ketide unit
(-CH2-CH2-) as a result of an additional round of chain
elongation and reduction by the Bref-PKS (Figure 4A and
Supplementary Figure S10). Due to the single-turnover nature
of the assay in the absence of the Bref-TH, compounds 7 and 8
could not be sufficiently obtained for structural elucidation.
Expression of Bref-PKS alone in yeast did not lead to detectable
amounts of 7 and 8 either. Therefore, to confirm compound 7
is indeed a nonaketide instead of octaketide, we performed the
in vitro assay using 2-13C-malonate and the MatB system, which
generates the 2-13C-malonyl-CoA in situ.24 As expected, an
increase of 9 mu in molecular weights was observed for both
labeled 7 and 8, confirming the incorporation of nine ketide
units derived from malonate into the backbone (Supplementary
Figure S8). Combining the UV and mass data (Supplementary
Figures S6 and S8), we propose the structure of 7 and 8 as
shown in Figure 4B, derived from an additional round of chain
elongation from 3 and 5, respectively, followed by full β-
reduction. Selected ion monitoring of the mass of 7 and 8 in
the Bref-PKS assay that contained Bref-TH yielded no trace of
these two compounds. These results demonstrate that in the
absence of the Bref-TH, the Bref-PKS functions primarily as a
nonaketide synthase.
A protein family database search of Bref-TH indicated that
the enzyme belongs to the Abhydrolase_6 family (E-value of
3.4 ×10−14). This diverse family is characterized by an α/β
hydrolase fold and functions via a proposed catalytic triad.25
Using Phyre2, we modeled the enzyme and identified the
putative catalytic triad to be S116, D247, and H276 that lie
within catalytic distances from each other (Supplementary
Figure S11B).26 Each residue was mutated to alanine, and the
resulting recombinant proteins were expressed and purified
from E. coli at comparable yields as wild-type for the in vitro
reaction with Bref-PKS.27 Adding either S116A or D247A
mutant to Bref-PKS resulted in a similar product profile (3−6)
as those seen with the wild type Bref-TH. Only the H276A
mutant failed to catalyze release of polyketide products and
yielded 7 as the major product upon base hydrolysis (Figure
4A). This suggests that only H276 is essential for the chain
length-specific hydrolysis of the PKS product, possibly serving
as the general base to facilitate the thiohydrolysis. We also
probed the specificity of the hydrolase-PKS interactions by
incubating Bref-PKS with CazE from the chaetoviridin
pathway22 and Fma-AT from the fumagillin pathway,28 both
known to participate in release of reduced polyketide products
from the respective HPPKS partners. In each case, the non-
cognate releasing enzymes did not lead to turnover of the
octaketides, and the nonaketide products were instead detected
using base hydrolysis (Figure 4A).
Chain-Length Control by the Releasing Enzyme Is
Also Observed in Other HRPKS Systems. To examine
whether chain-length regulation by the releasing enzyme is also
Figure 5. Fma-PKS produces longer polyenes in the absence of cognate Fma-AT. (A) HPLC profiles of Fma-PKS with Fma-AT; base hydrolysis; or
Bref-TH. Fma-PKS produces a hexaketide polyene in the presence of the partner Fma-AT. In its absence or in the presence of the non-cognate Bref-
TH, the PKS catalyzes 1 or 2 more extension steps to yield the heptaketide 10 and octaketide 11. The reactions consist of 20 μM Fma-PKS, 2 mM
mCoA, and 2 mM NADPH with either 20 μM of the releasing enzyme or base hydrolysis (1 M NaOH at 65 °C for 10 min). (B) Proposed structures
of the polyene compounds produced in the in vitro assay.
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observed in other HRPKSs, we assayed the Fma-PKS involved
in the biosynthesis of the polyene portion of the meroterpenoid
fumagillin. Fma-PKS was previously shown to produce the
highly conjugated hexaketide pentaenoic acid 9 ([M + H+] 191,
λmax 358 nm) in the presence of its releasing acyltransferase
partner, Fma-AT.28 When the Fma-PKS assay was performed in
the absence of Fma-AT and subjected to base-hydrolysis
followed by extraction, two new products were observed, 10
([M + H] + 217) and 11 ([M + H] + 243), with λmax of 378 and
398 nm, respectively. The periodic increases in both mass (+26
mu) and λmax compared to 9 therefore strongly indicate 10 and
11 are heptaketide and octaketide polyenes, respectively, as
shown in Figure 5. This is also verified by the in vitro labeling
studies with 2-13C-malonate that showed the corresponding
mass shift of +7 and +8 for 10 and 11, respectively
(Supplementary Figure S12 and S13). When Bref-TH is used
in the reaction with Fma-PKS, 10 and 11 were also dominantly
produced relative to 9 (Figure 5A).
Discussion. In this work, we identified a gene cluster in E.
brefeldianum that is most likely to be involved in the
biosynthesis of the protein transporter inhibitor BFA. BFA is
a fungal polyketide that is derived from a highly reduced
polyketide synthesized by a HRPKS. The Bref-PKS along with
a partnering Bref-TH were reconstituted in S. cerevisiae and in
vitro. The reconstitution experiments showed that the
dominant product of Bref-PKS in the presence of Bref-TH is
an acyclic polyketide 3 that is of the same length as BFA and
exhibited the expected β-reduction patterns for downstream
conversion into BFA (Figure 1). Unexpectedly, Bref-PKS
synthesized longer polyketide products in the absence of Bref-
TH, implicating an important role of Bref-TH in controlling the
chain length of the HRPKS. This phenomenon was also
observed in the Fma-PKS and Fma-AT pair involved in
fumagillin biosynthesis. The in vitro reconstitution studies
reported here were crucial in enabling single turnover
experiments (chemical hydrolysis) that were not observable
under in vivo conditions.
Reduced polyketides synthesized by HRPKSs require
accessory enzymes for product release. In most cases, this is
completed by an assortment of enzymes belonging to the α−β
hydrolase family. The protein−protein interaction between the
HRPKS and the releasing enzyme, which facilitates product
turnover and chain length control, is therefore an intricate part
of the overall programming rule of these enzymes. When the
releasing enzyme is an acyltransferase, the polyketide is either
transferred to the hydroxyl group of a small molecule acceptor
such as catalyzed by LovD in lovastatin biosynthesis29 or the
free thiol of the ACP domain of a partnering PKS catalyzed by
the Starter-Unit:ACP acyltransferase (SAT) in dual PKS
systems.7,8,30 Thiohydrolases such as Bref-TH hydrolyzes the
polyketide thioester to release the product. Other examples of
TH include LovG that hydrolyses dihydromonacolin L from
LovB.31 Interestingly, the releasing α−β hydrolases are widely
varied in sequences and also in catalytic mechanisms. Whereas
LovD, LovG, and SAT domains utilize covalent catalysis via
active site nucleophiles, enzymes such as Bref-TH and CazE
apparently operate via noncovalent, general base catalysis
similar to the trichothecene acyltransferase.32 Each releasing
enzyme is also highly specific for the partnering HRPKS ACP
domain, as shown in our results. This exclusive protein−protein
interaction likely arose during evolution to ensure minimal
crosstalk between HRPKS gene clusters, as well as triggering
allosteric structural changes required for catalysis.33
Using the Bref-PKS and Bref-TH pair (as well as the Fma
pair), we showed that the releasing enzyme is important in
ensuring the proper chain length control of HRPKSs. In the
absence of the TH enzymes, both Bref-PKS and Fma-PKS
synthesized longer products than what is reflected in the final
product. This result can be rationalized in a competition model
in which the polyketide chain can be either offloaded by the
TH/AT at the correct size or can be recaptured by the KS
domain for another round of elongation (Figure 6). In the
absence of the TH, the polyketide chain remains attached to
the ACP domain, which allows reentry into the KS domain. If
the KS can accommodate a product of longer size, an additional
extension step can take place as observed in products 7 and 10.
We did not detect any shorter polyketides in the in vitro assays,
Figure 6. Summary of the programming rules exhibited by Bref-PKS.
From the in vitro studies, we were able to fully reconstitute the
complex programming of this model HRPKS. Bref-PKS uses different
permutations of the reductive domains at each extension cycle and
selectively offloads the correct octaketide products with the partner
Bref-TH or the longer nonaketide products with base hydrolysis.
Compounds 4 and 6 that resulted from additional enoyl reduction at
the final extension are italicized.
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indicating the high substrate specificities of the TH toward the
correct acyl group. However, when equimolar amount of Bref-
TH was added 16 h after initiation of the in vitro Bref-PKS
reaction, the longer nonaketide products (7 and 8) were again
observed at similar levels as the base-hydrolyzed reaction
(Supplementary Figure S10). This indicates that Bref-TH is
capable of hydrolyzing longer chain length but preferably
hydrolyzes the correct octaketide chain in a timely manner
when co-incubated with Bref-PKS. Interestingly, in both Bref-
PKS and Fma-PKS, the extra ketide(s) that form as a result of
excluding the TH in the reaction were completely processed by
the available reduction domains. The recognition of the longer
(and unnatural) substrates by these domains may similarly be
due to stalling of the polyketide on the ACP domain, which led
to the observed modification. Detailed kinetics studies using
model substrates of varying length will provide insights into the
substrate specificities of these tailoring domains.
These results support that the KS domain remains an
important element in determining polyketide chain length. This
is also evident in the phylogeny based classification of HRPKSs
using KS domain sequences, which led to clading of the
HRPKSs based on chain size (short, medium, and long, as
shown in Supplementary Figure S3). Additionally, some
HRPKS systems appear to maintain a high fidelity in producing
the correct product chain length; for instance, both lovastatin
diketide and nonaketide synthases always produce the correct
chain length,5,29 as well as the solanapyrone synthase that
releases the product via pyrone formation.34 However, as
demonstrated here in Bref-PKS and Fma-PKS, these domains
appear to also have some flexibility on the chain length
programming and are insufficient to terminate at the correct
chain length alone. In other words, KS domains are capable of
synthesizing products of longer size without downstream
enzyme control. This may rationalize an in vivo study involving
the biosynthesis of fumonisins. Zhu et al. reported a successful
complementation of the C16-PKS ALT1 for the C18-PKS
FUM1-disruption strain to yield the C18 fumonisins.
35 In this
case, offloading of the polyketide via a decarboxylative
condensation with an alanine by Fum8 dictates the ultimate
chain length in the final product.36 Releasing enzyme control of
chain length was also observed in the HRPKS-NRPS involved
in the biosynthesis of preaspyridone, a precursor of the natural
product aspyridone. In that example, when the fused NRPS
module was excised from the megasynthetases, the PKS module
was able to synthesize a polyketide product that is longer than
that present in preaspyridone (pentaketide instead of
tetraketide).9 That is again most likely due to stalling of the
polyketide chain on the PKS in the absence of a downstream
domain (C domain in the NRPS) that offloads the correctly
sized polyketide for subsequent modification. Additional factors
that affect chain length control outside of KS were previously
reported, such as the KR-dependent product size observed in
PKS-NRPS domain swapping experiments.37
While it may appear that some HRPKSs become aberrant in
their chain-length control in the absence of cognate releasing
partners, it could be argued that these HRPKSs might have
originated from ancestral PKS clusters that synthesize final
products of longer chain length. In other words, this is Nature’s
alternative and quick way of generating chain length diversity
without modifying the KS or other PKS components, which
could be more difficult. In this way, the same HRPKS can be
adapted to produce polyketide products of different chain
lengths by partnering with releasing enzymes of different chain
length specificities. Thus, Bref-PKS may have originated from
an ancestral HRPKS cluster that produces a nonaketide product
but was adapted to produce octaketide by coupling with the
Bref-TH with shorter chain length specificity. This lesson from
Nature has important implications for engineering of polyketide
biosynthesis, as it suggests that we can attempt to alter the
chain length specificity of the releasing enzyme instead of
focusing on the HRPKS components to manipulate the chain
length of the final product.
Implications of in Vitro Bref-PKS Data on the Biosynthesis
of Brefeldin A. In light of the results of the reconstitution
studies on Bref-PKS, we can improve our current under-
standing of the biosynthesis of BFA. From our data, we can
conclude that Bref-PKS and Bref-TH are minimally required to
produce the octaketide backbone of BFA. Additionally, Bref-
PKS is capable of producing the correctly tailored intermediate
for further modification to achieve the final structure of BFA.
The C2−C3 and C10−C11 double bonds are identical to those
in BFA, while the C4−C5 double bond is strategically placed in
3 to allow a proposed radical addition to the double bond
leading to the intramolecular annulation that installs the
cyclopentane ring (Supplementary Figure S14). The actual
mechanism would require additional studies on the enzymes
encoded by the genes in the bref cluster. We have also
demonstrated that Bref-PKS synthesizes products with variable
degrees of reduction, which explains the isolation of some BFA
analogues, such as the unlactonized 7-dehydrobrefeldin A
acid.14
The mechanism for macrolactonization of BFA is an
intriguing aspect of the biosynthesis. Unlike the RAL systems,
Bref-PKS does not partner with an NR-PKS that uses an in cis
thioesterase for macrolactonization. However, we propose that
the Bref-TH could similarly perform both offloading and
lactonization, as it is the only candidate gene transcribed in the
bref cluster. It is foreseeable that the mechanism would involve
the C15-hydroxyl that has been observed in in vitro product 3,
which is the proper position for an intramolecular attack on the
thioester bond. The catalytic His276 could deprotonate the
C15-hydroxyl group and make it a suitable nucleophile for
lactonization. Our observation that all of the products were
linear, however, indicates the necessity of having the cyclo-
pentane ring form first to “bend” the molecule and bring the
nucleophile closer to the ACP to direct lactonization (bottom
scheme in Figure 1). This is in contrast to what was previously
hypothesized, where the macrolactonization precedes the
cyclopentane ring formation.17 Mabuni et al. originally
proposed a mechanism involving a C4−C5 epoxide inter-
mediate. However, this epoxide-opening mechanism requires
an alkene at C9−C10, which is an unusual position in a
polyketide chain.17 Recently, Zhang et al. proposed an
NADPH-dependent reductive cyclization catalyzed by the
alcohol dehydrogenase IkaC for the formation of a five-
membered ring within the macrolactam ikarugomycin.38
However, we did not find a homologue of this enzyme in the
bref cluster. In light of the structure of 3 produced by Bref-PKS,
we propose a mechanism via a C9 radical intermediate
catalyzed by a P450 enzyme (Supplementary Figure S14).
Addition of the C9 radical to the C4−C5 alkene followed by an
oxygen rebound will result in the cyclopentane ring and C4-
hydroxyl of 1. The actual cyclization mechanism will be the
subject of further investigations, including determining the roles
of the P450s in the cluster. Additionally, the role of Bref-TH in
the lactonization of BFA should also be probed in the future.
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As noted earlier, Bref-TH homologue is found in the vicinity
of a Bref-PKS homologue in Trichoderma virens. Such HRPKS/
in trans-TH pairs are also found in several other fungal
genomes, including Aspergillus nidulans (AN7084.2/7083.2),
Botryotinia fuckeliana (BcDW1_1087/1086), Neofusicoccum
parvum (UCNRP2-2180/2181), and Macrophomina phaeseolina
(MPH_06436/06434). These HRPKS/TH pairs may be
responsible for production of similar linear reduced polyketide
or macrolide compounds. Several non-RAL macrolides have
been previously isolated from fungi such as putaminoxin,39
pinolidoxin,40 and balticolid;41 the discovery and character-
ization of the Bref-PKS and Bref-TH therefore provide leads to
the biosynthetic gene clusters that are responsible for
production of such fungal macrolide scaffolds.
Conclusion. HRPKSs are still poorly understood enzymes
that catalyze the synthesis of a wide array of compounds. In
order to harness their biosynthetic potential, it is important to
first improve our understanding of the underlying mechanism
behind their activities by finding a model PKS to work with. In
this paper, we report the heterologous expression and
reconstitution of Bref-PKS involved in the biosynthesis of
BFA to characterize the HRPKS programming rules in vitro.
This system has the advantage of being a standalone enzyme
with a sizable product and different reduction patterns at each
extension. Using this HRPKS, we uncovered an NADPH-
dependent reductive tailoring by the PKS in synthesizing
products of mixed reduction. We also demonstrated that chain-
length determination is not dictated by the KS domain alone
but can be altered by the releasing enzyme. Such strategy could
be Nature’s way of generating chain length diversity without
having to evolve the large multidomain megasynthases. The
TH-mediated control is highly specific with respect to protein−
protein interactions, as well as on acyl substrate recognition.
This study further underscores the importance of including
tailoring enzyme functions in relating and predicting fungal
HRPKS and their products.
■ METHODS
Strain and Culture Conditions. E. brefeldianum ATCC 58665
was obtained from ATCC and maintained in GMM or SMM agar at
28 °C. For BFA production and for mRNA extraction, the strain was
grown in liquid MEM media at RT with 250 rpm shaking.42
Saccharomyces cerevisiae BJ5464 was used for protein expression of bref-
PKS and subsequent in vivo production of 3−6. This strain was
maintained and cultured in YPD, while the transformants carrying the
recombinant plasmids were grown in synthetic defined dropout media
with appropriate supplements. E. coli TOPO 10 was used for the
subcloning steps, and E. coli BL21(DE3) was used for expressing bref-
TH.
Sequencing and Bioinformatic Analysis. The genomic DNA of
E. brefeldianum was prepared from mycelium grown in stationary liquid
culture.43 Shotgun sequencing was performed at GenoSeq (UCLA
Genotyping and Sequencing Core) with the GS FLX Titanium system
(Roche) and at Ambry Genetics (Aliso Viejo, CA) using Illumina
Hiseq 2000. The reads were assembled into contigs using SOAP-
deNOVO.44 The contigs were formatted to BLAST database format
for local BLAST search using standalone BLAST software (v. 2.2.18).
Gene predictions were performed using the FGENESH program
(Softberry) and manually checked by comparing with homologous
gene/proteins in the GenBank database. Functional domains in the
translated protein sequences were predicted using Conserved Domain
Search (NCBI). Modeling and alignment of the Bref-hydrolase was
performed using Phyre2 server,26 and the image was generated using
Boxshade 3.21.
Expression Analysis by Reverse Transcription Polymerase
Chain Reaction (RT-PCR). The total RNA of E. brefeldianum ATCC
58665 was extracted from the culture grown in MEM media using the
Ambion RNA extraction kit. The first strand cDNA was synthesized
using the Oligo-dT primer and Improm-II reverse transcription system
(Promega) according to the manufacturer’s instructions. Desired
cDNA was then amplified with GoTaq Green Master Mix (Promega)
using gene-specific primers synthesized by Integrated DNA Tech-
nologies (Supplementary Table S2). gDNA template (previously
prepared) was used for comparison using the same primer mix as the
cDNA reaction.
Molecular Genetic Manipulation. Polymerase chain reactions
for cloning were performed using Phusion high-fidelity DNA
polymerase (New England Biolabs) or Platinum Pfx DNA polymerase
(Invitrogen). PCR products were cloned into a PCR-Blunt vector
(Invitrogen) for DNA sequencing and subcloning. Restriction
enzymes (New England Biolabs) and T4 ligase (Invitrogen) were
used, respectively, for the digestion and ligation of DNA fragments. All
primers were ordered from IDT (Supplementary Table S2).
The intron-less transcript of bref-TH was obtained by amplification
from the cDNA (as prepared previously) using primers containing the
EcoRI and NotI restriction sites. The PCR product was digested with
the corresponding enzymes and ligated to the linearized pHis8
vector.45 The correct construct (designated pAZ93) was PCR-verified
and sequenced to ensure intact ORF. pAZ93 was also used as the
template for constructing the yeast plasmid (Trp3 marker) for the
double transformation experiments with bref-PKS (pAZ112), as well as
for constructing the bref-TH single and triple mutants using transfer
PCR.27
To construct the intron-less transcript of bref-PKS, the 7.3-kb gene
was divided into 5 equal-sized fragments; each fragment was amplified
from the cDNA (as prepared previously) and was subcloned into
PCR-blunt vector and sequence-verified with M13 primers to confirm
absence of introns. After confirmation, the respective pieces were
reamplified from the PCR-blunt subcloning constructs with primers
that contain overlapping regions to the next segment of the gene. The
pieces were transformed together with the linearized vector backbone
derived from YEplac195 containing the ADH2 promoter and
terminator with N-terminus FLAG-tag and C-terminus hexahistidine
tag46 into S. cerevisiae BJ5464-NpgA47 using S. c. EasyComp
Transformation Kit (Invitrogen) and selected on uracil-dropout
semisynthetic media. The resulting transformants were screened by
colony-PCR, and the plasmid in the correct transformant was rescued
using the Zymoprep Yeast Plasmid Miniprep Kit (Zymo Research)
and transformed into E. coli for propagation and sequencing
verification. The resulting plasmid was designated pAZ94.
Protein Expression and in Vitro Reactions. The bref-TH-pHis8
construct (pAZ93) was transformed into BL21(DE3) via electro-
poration and cultured and induced with IPTG for expression. The His-
tagged protein was purified using nickel-affinity chromatography. The
mutant hydrolases were expressed and purified the same way as the
wild type. Similarly, the bref-PKS construct (pAZ94) was retrans-
formed into the yeast host for protein expression, as described
elsewhere,48 and subsequently purified using nickel-affinity chroma-
tography and eluted using 250 mM imidazole.
Unless otherwise stated, the reactions involving Bref-PKS were set
up on ice in mixtures containing 100 mM phosphate buffer, 0.5 to 10
mM NADPH, 2 mM malonyl-CoA, and Bref-PKS and Bref-TH
enzymes (typically 20 μM) to a final volume of 100 μL. The reactions
were left at RT overnight, extracted with 2 × 200 μL ethyl acetate with
0.1% acetic acid, and dried completely for analysis. In cases where base
hydrolysis was performed, 10 μL of 1 M NaOH was added first, and
the reaction was heated to 65 °C before extraction with the organic
solvent.
For the 13C labeling experiments, Bref-PKS was incubated with 20
μM MatB, 10 μM ATP, 10 mM NADPH, 100 mM [2-13C]-malonate,
10 mM Mg2Cl2, 25 mM ATP, 10 mM CoA, 25 μM MatB, and 1 mM
NADPH in 100 mM PBS buffer, pH 7.4 in 100 μL total volume. The
reactions were performed at RT overnight and either directly extracted
with ethyl acetate + 0.1% acetic acid or base-hydrolyzed using 1 M
NaOH.
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In Vivo Culturing and Extraction of Compounds. pAZ94 (bref-
PKS, ura3 marker) and pAZ112 (bref-TH, trp3 marker) were
cotransformed into S. cerevisiae BJ5464-NpgA47 using S. c. EasyComp
Transformation Kit (Invitrogen) and selected on uracil- and
tryptophan-dropout semisynthetic media. The transformants were
PCR-screened to confirm the presence of both plasmids, and the
correct colony was grown on minimal media as seed culture for 3 days.
Subsequently, the seed culture was diluted 1000× into 1 L of YPD and
grown for at most 3 days at 28 °C with shaking at 250 rpm. The
metabolites were monitored daily by sampling 500 μL of the culture
and extracting with equal volume of ethyl acetate + 0.1% acetic acid for
LC−MS analysis. For purification of compounds, 3 and 5 were
harvested at the optimal production of 36 h, while 4 and 6 were
extracted after 72 h. Twenty grams of Amberlite XAD02 polymeric
adsorbent resin (Supelco) was added to the media after centrifugation
of the cells to extract the organic compounds and was left overnight
with shaking. The resin was collected by filtration, and the compounds
were eluted using acetone. The solvent was dried, and the residue was
partitioned with chloroform/water. The chloroform fraction was then
dried completely and flash separated using the CombiFlash system. A
C18 column was used with a water and acetonitrile solvent system.
The fractions were analyzed, and those containing the desired
compounds were pooled together for the final purification using
semipreparative HPLC with Phenomenex Luna 5 μL 250 × 1000 mm
C18 reverse phase column using an acetonitrile/water + 0.1% formic
acid solvent system.
LC−MS Analysis. The dried samples were first dissolved in
methanol and centrifuged for 8 min before being injected to the
Shimadzu 2010 EV liquid chromatography mass spectrometer with
positive and negative electrospray ionization and Phenomenex Luna 5
μL 2.0 × 10 mm C18 reverse-phase column. The samples were
resolved on a linear gradient from 5% to 95% with a CH3CN/H2O +
0.05% formic acid solvent system for 30 min.
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